{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:30:10Z","timestamp":1791811810385,"version":"4.3.4"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UGC-MRP","award":["41-1266\/2012"],"award-info":[{"award-number":["41-1266\/2012"]}]},{"name":"ICMR-BMS","award":["2012-2656"],"award-info":[{"award-number":["2012-2656"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.phrs.2015.05.010","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T01:16:29Z","timestamp":1433466989000},"page":"86-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"special_numbering":"C","title":["Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action"],"prefix":"10.1016","volume":"99","author":[{"given":"Vikas","family":"Dutt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Dabur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Injeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.05.010_bib0805","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.biocel.2005.04.018","article-title":"Skeletal muscle hypertrophy and atrophy signalling pathways","volume":"37","author":"Glass","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0810","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exger.2005.04.003","article-title":"Apoptosis in muscle atrophy: relevance to sarcopenia","volume":"40","author":"Dupont-Versteegden","year":"2005","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0815","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mehy.2006.11.043","article-title":"Signaling mechanisms involved in disuse muscle atrophy","volume":"69","author":"Zhang","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2015.05.010_bib0820","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbadis.2008.10.011","article-title":"The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and trophy","volume":"1782","author":"Murton","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2015.05.010_bib0825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1152\/physiolgenomics.00042.2009","article-title":"Evidence of MyomiR network regulation of beta-myosin heavy chain gene expression during skeletal muscle atrophy","volume":"39","author":"McCarthy","year":"2009","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.phrs.2015.05.010_bib0830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MCO.0b013e328351c3fc","article-title":"TWEAK and TRAF6 regulate skeletal muscle atrophy","volume":"15","author":"Kumar","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.phrs.2015.05.010_bib0835","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1083\/jcb.200909117","article-title":"The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice","volume":"188","author":"Mittal","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0840","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-008-0373-8","article-title":"Nuclear factor-kappa B signaling in skeletal muscle atrophy","volume":"86","author":"Li","year":"2008","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"1","key":"10.1016\/j.phrs.2015.05.010_bib0845","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(98)00216-X","article-title":"Different cytokines modulate ubiquitin gene expression in rat skeletal muscle","volume":"133","author":"Llovera","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2015.05.010_bib0850","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1152\/japplphysiol.00089.2007","article-title":"Protein kinase B\/Akt: a nexus of growth factor and cytokine signalling in determining muscle mass","volume":"103","author":"Frost","year":"2007","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0855","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.freeradbiomed.2009.07.002","article-title":"Are antioxidants useful for treating skeletal muscle atrophy?","volume":"47","author":"Bonetto","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2015.05.010_bib0860","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1242\/dmm.010389","article-title":"Cellular and molecular mechanisms of muscle atrophy","volume":"6","author":"Bonaldo","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.phrs.2015.05.010_bib0865","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mce.2014.06.012","article-title":"Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4\/cAMP\/EPAC\/PI3K\/Akt pathway","volume":"393","author":"Joshi","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0870","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1152\/ajpendo.00188.2011","article-title":"Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt","volume":"302","author":"Goncalves","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib0875","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jor.22482","article-title":"Differential ubiquitin\u2013proteasome and autophagy signaling following rotator cuff tears and suprascapular nerve injury","volume":"32","author":"Joshi","year":"2014","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib0880","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cell.2008.09.055","article-title":"Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation","volume":"135","author":"Duncan","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.05.010_bib0885","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1562","article-title":"Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers","volume":"147","author":"Takahashi","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.phrs.2015.05.010_bib0890","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1096\/fj.01-0866com","article-title":"Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy","volume":"16","author":"Hunter","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2015.05.010_bib0895","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2015.05.010_bib0900","first-page":"805","article-title":"Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia","volume":"22","author":"Melstrom","year":"2007","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0905","doi-asserted-by":"crossref","first-page":"e45900","DOI":"10.1371\/journal.pone.0045900","article-title":"Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia","volume":"7","author":"Vaughan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.05.010_bib0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.advms.2013.11.001","article-title":"Anorexia\u2013cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach","volume":"59","author":"Ronga","year":"2014","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.phrs.2015.05.010_bib0915","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fphys.2014.00088","article-title":"Pancreatic cancer cachexia: a review of mechanisms and therapeutics","volume":"5","author":"Tan","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0920","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-511X-7-24","article-title":"The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation","volume":"7","author":"Magee","year":"2008","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.phrs.2015.05.010_bib0925","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3945\/jn.113.176255","article-title":"Fish oil increases muscle protein mass and modulates Akt\/FOXO, TLR4, and NOD signaling in weanling piglets after lipopolysaccharide challenge","volume":"143","author":"Liu","year":"2013","journal-title":"J. Nutr."},{"key":"10.1016\/j.phrs.2015.05.010_bib0930","first-page":"3604","article-title":"Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid","volume":"61","author":"Whitehouse","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib0935","first-page":"159","article-title":"Pathogenesis of cancer cachexia","volume":"1","author":"Tisdale","year":"2003","journal-title":"J. Support Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0940","first-page":"209","article-title":"The ubiquitin\u2013proteasome pathway as a therapeutic target for muscle wasting","volume":"3","author":"Tisdale","year":"2005","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0945","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ydbio.2004.08.015","article-title":"Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal","volume":"275","author":"Olguin","year":"2004","journal-title":"Dev. Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0950","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1179\/174313208X281046","article-title":"Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice","volume":"30","author":"Berardi","year":"2008","journal-title":"Neurol. Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib0955","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/mnfr.201000176","article-title":"c9t11-Conjugated linoleic acid-rich oil fails to attenuate wasting in colon-26 tumor-induced late-stage cancer cachexia in male CD2F1 mice","volume":"55","author":"Tian","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib0960","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-011-0028-4","article-title":"Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise","volume":"2","author":"Penna","year":"2011","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib0965","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/tox.20546","article-title":"Protective effects of eicosapentaenoic acid on genotoxicity and oxidative stress of cyclophosphamide in mice","volume":"26","author":"Li","year":"2011","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0970","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbrc.2008.08.004","article-title":"Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA)","volume":"375","author":"Khal","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2015.05.010_bib0975","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11010-006-9256-x","article-title":"Altered PPARgamma expression inhibits myogenic differentiation in C2C12 skeletal muscle cells","volume":"294","author":"Singh","year":"2007","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.phrs.2015.05.010_bib0980","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.clnu.2012.11.013","article-title":"Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice","volume":"32","author":"Mauricio","year":"2013","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.phrs.2015.05.010_bib0985","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort","volume":"22","author":"Jatoi","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0990","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","article-title":"Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia","volume":"24","author":"Fearon","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib0995","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bjc.2011.391","article-title":"Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia","volume":"105","author":"Murphy","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1000","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/0008-5472.277.65.1","article-title":"Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss","volume":"65","author":"Smith","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1005","doi-asserted-by":"crossref","first-page":"E923","DOI":"10.1152\/ajpendo.00314.2007","article-title":"Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli","volume":"293","author":"Eley","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1010","doi-asserted-by":"crossref","first-page":"e102947","DOI":"10.1371\/journal.pone.0102947","article-title":"\u03b2-Hydroxy \u03b2-methylbutyrate improves dexamethasone-induced muscle atrophy by modulating the muscle degradation pathway in SD rat","volume":"9","author":"Noh","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.05.010_bib1015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0148607113502545","article-title":"Elderly persons with ICU-acquired weakness: the potential role for \u03b2-hydroxy-\u03b2-methylbutyrate (HMB) supplementation?","volume":"38","author":"Rahman","year":"2013","journal-title":"J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.phrs.2015.05.010_bib1020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0002-9610(02)00823-1","article-title":"Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine","volume":"183","author":"May","year":"2002","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.phrs.2015.05.010_bib1025","doi-asserted-by":"crossref","first-page":"e011752","DOI":"10.1371\/journal.pone.0117520","article-title":"\u03b2-Hydroxy-\u03b2-methylbutyrate (HMB) normalizes dexamethasone-induced autophagy-lysosomal pathway in skeletal muscle","volume":"10","author":"Gir\u00f3n","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.05.010_bib1030","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.exger.2013.06.005","article-title":"\u03b2-Hydroxy-\u03b2-methylbutyrate (HMB) enhances the proliferation of satellite cells in fast muscles of aged rats during recovery from disuse atrophy","volume":"48","author":"Alway","year":"2013","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000369718","article-title":"Modulation of SIRT1-Foxo1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance","volume":"35","author":"Sin","year":"2015","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.phrs.2015.05.010_bib1040","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbrc.2011.11.154","article-title":"Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism","volume":"417","author":"Alamdari","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2015.05.010_bib1045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.intimp.2014.02.002","article-title":"Resveratrol prevents TNF-\u03b1-induced muscle atrophy via regulation of Akt\/mTOR\/FoxO1 signaling in C2C12 myotubes","volume":"19","author":"Wang","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clnu.2006.12.001","article-title":"Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models","volume":"26","author":"Busquets","year":"2007","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.phrs.2015.05.010_bib1055","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.fct.2009.06.002","article-title":"Safety studies conducted on high-purity trans-resveratrol in experimental animals","volume":"47","author":"Williams","year":"2009","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1060","doi-asserted-by":"crossref","first-page":"E853","DOI":"10.1152\/ajpendo.00048.2011","article-title":"Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats","volume":"301","author":"Chen","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1065","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1096\/fj.10-177295","article-title":"Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat","volume":"25","author":"Momken","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1070","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/sj.bjc.6602165","article-title":"Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation","volume":"91","author":"Wyke","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/01635581.2011.563032","article-title":"Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo","volume":"63","author":"Shadfar","year":"2011","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12931-014-0156-4","article-title":"Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats","volume":"15","author":"Qi","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1085","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1055-9965.EPI-07-0022","article-title":"Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent","volume":"16","author":"Boocock","year":"2007","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.phrs.2015.05.010_bib1090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2014.08.003","article-title":"The resveratrol fiasco","volume":"90","author":"Visioli","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1378\/chest.128.3.1187","article-title":"Treatment of cachexia with ghrelin in patients with COPD","volume":"128","author":"Nagaya","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2015.05.010_bib1100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ki.2009.411","article-title":"Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease","volume":"77","author":"Barazzoni","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2015.05.010_bib1105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2015.05.010_bib1110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MCO.0000000000000049","article-title":"Acylated and unacylated ghrelin administration to blunt muscle wasting","volume":"17","author":"Reano","year":"2014","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.phrs.2015.05.010_bib1115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.mce.2011.12.021","article-title":"Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats","volume":"351","author":"Sheriff","year":"2012","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2014.09.025","article-title":"Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice","volume":"743","author":"Tsubouchi","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1125","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","article-title":"Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure","volume":"110","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.05.010_bib1130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2011.07.086","article-title":"Therapeutic potential of ghrelin treatment for unloading-induced muscle atrophy in mice","volume":"412","author":"Koshinaka","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2015.05.010_bib1135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","article-title":"Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: a randomised, placebo-controlled, doubleblind, double-crossover study","volume":"98","author":"Strasser","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/eje.0.1500447","article-title":"Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects","volume":"150","author":"Akamizu","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia\u2013cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib1155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia\u2013cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1160","doi-asserted-by":"crossref","first-page":"C475","DOI":"10.1152\/ajpcell.00088.2004","article-title":"The COX-2 pathway is essential during early stages of skeletal muscle regeneration","volume":"287","author":"Bondesen","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.103.063099","article-title":"Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting","volume":"308","author":"Davis","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.05.010_bib1170","first-page":"223","article-title":"Molecular analysis of xenograft models of human cancer cachexia\u2014possibilities for therapeutic intervention","volume":"4","author":"Baumgarten","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.phrs.2015.05.010_bib1175","first-page":"649","article-title":"Effect of cyclooxygenase-2 inhibition by meloxicam, on atrogin-1 and myogenic regulatory factors in skeletal muscle of rats injected with endotoxin","volume":"63","author":"Martin","year":"2012","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.phrs.2015.05.010_bib1185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1097-0215(20000701)87:1<95::AID-IJC14>3.0.CO;2-D","article-title":"Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model","volume":"87","author":"Hussey","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.phrs.2015.05.010_bib1195","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1476-5381.2010.00957.x","article-title":"Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits","volume":"161","author":"Romero","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1200","doi-asserted-by":"crossref","first-page":"E1656","DOI":"10.1152\/ajpendo.00502.2006","article-title":"Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation","volume":"292","author":"Granado","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1205","doi-asserted-by":"crossref","first-page":"C1490","DOI":"10.1152\/ajpcell.00255.2010","article-title":"p300 acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle","volume":"300","author":"Senf","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"Pt 7","key":"10.1016\/j.phrs.2015.05.010_bib1210","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1242\/jcs.136390","article-title":"HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy","volume":"127","author":"Beharry","year":"2014","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.phrs.2015.05.010_bib1215","doi-asserted-by":"crossref","first-page":"16977","DOI":"10.1073\/pnas.0601565103","article-title":"Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade","volume":"103","author":"Tang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.05.010_bib1220","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1091\/mbc.E08-07-0759","article-title":"A histone deacetylase 4\/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression","volume":"20","author":"Tang","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.phrs.2015.05.010_bib1225","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1093\/hmg\/dds286","article-title":"Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice","volume":"21","author":"Bricceno","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2015.05.010_bib1230","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2015.05.010_bib1235","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2174\/156800909789057015","article-title":"Deacetylase inhibitors modulate the myostatin\/follistatin axis without improving cachexia in tumor-bearing mice","volume":"9","author":"Bonetto","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.phrs.2015.05.010_bib1240","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","article-title":"Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia","volume":"391","author":"Benny Klimek","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2015.05.010_bib1245","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2015.05.010_bib1250","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.05.010_bib1255","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1096\/fj.08-115618","article-title":"Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy","volume":"23","author":"Colussi","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/bj3610185","article-title":"Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin\u2013proteasome-dependent proteolysis in cancer and septic rats","volume":"361","author":"Combaret","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1265","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.1074\/jbc.M110856200","article-title":"Differential signalling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation","volume":"277","author":"Mei","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.05.010_bib1270","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.cellsig.2005.03.011","article-title":"Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline","volume":"17","author":"Brennesvik","year":"2005","journal-title":"Cell Signal."},{"key":"10.1016\/j.phrs.2015.05.010_bib1275","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/jir.2009.0021","article-title":"Modulation of cytokine production by cyclic adenosine monophosphate analogs in human leukocytes","volume":"30","author":"Gerlo","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00424-009-0747-y","article-title":"Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology","volume":"459","author":"Metrich","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.phrs.2015.05.010_bib1285","first-page":"E660","article-title":"Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis","volume":"265","author":"Breuill\u00e9","year":"1993","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1290","doi-asserted-by":"crossref","first-page":"E702","DOI":"10.1152\/ajpendo.00147.2006","article-title":"Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats","volume":"292","author":"Baviera","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1006955832323","article-title":"Manipulation of the ubiquitin\u2013proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats","volume":"26","author":"Combaret","year":"1999","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.phrs.2015.05.010_bib1300","first-page":"520","article-title":"Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity","volume":"78","author":"Semmler","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2015.05.010_bib1305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3600143","article-title":"Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting","volume":"360","author":"Deval","year":"2001","journal-title":"Biochem. J."},{"issue":"2008","key":"10.1016\/j.phrs.2015.05.010_bib1310","first-page":"1950","article-title":"Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia","volume":"105","author":"Steffen","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1315","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mus.20416","article-title":"Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy","volume":"32","author":"Hinkle","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.phrs.2015.05.010_bib1320","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1210\/en.2009-0428","article-title":"Mechanisms involved in 3\u2032,5\u2032-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin\u2013proteasome system in skeletal muscle","volume":"150","author":"Goncalves","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2015.05.010_bib1325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2044-5040-1-29","article-title":"The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis","volume":"1","author":"Knight","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib1330","doi-asserted-by":"crossref","first-page":"e24714","DOI":"10.1371\/journal.pone.0024714","article-title":"CREB is activated by muscle injury and promotes muscle regeneration","volume":"6","author":"Stewart","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.05.010_bib1335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pharmthera.2008.06.003","article-title":"The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting","volume":"120","author":"Ryall","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.05.010_bib1340","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1039\/c3mb70134d","article-title":"Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice","volume":"9","author":"Quanjun","year":"2013","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.phrs.2015.05.010_bib1345","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.biocel.2013.07.019","article-title":"Regulation of Akt-mTOR, ubiquitin\u2013proteasome and autophagy\u2013lysosome pathways in response to formoterol administration in rat skeletal muscle","volume":"45","author":"Joassard","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1350","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13539-014-0153-y","article-title":"Formoterol in the treatment of experimental cancer cachexia: effects on heart function","volume":"5","author":"Toledo","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib1355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.rmed.2009.07.016","article-title":"Exercise capacity and cytochrome oxidase activity in muscle mitochondria of COPD patients","volume":"104","author":"D\u2019Agostino","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.phrs.2015.05.010_bib1360","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1165\/rcmb.2012-0167OC","article-title":"Skeletal muscle oxidative metabolism in an animal model of pulmonary emphysema: formoterol and skeletal muscle dysfunction","volume":"48","author":"Sullo","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1365","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-04-0425","article-title":"Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting","volume":"64","author":"Busquets","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3892\/ol.2011.442","article-title":"Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats","volume":"3","author":"Busquets","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2015.05.010_bib1375","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1096\/fj.05-5125fje","article-title":"Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy","volume":"20","author":"Steelman","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1380","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jcp.20757","article-title":"Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-\u03baB-independent. FoxO1-dependent mechanism","volume":"209","author":"McFarlane","year":"2006","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1385","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coph.2006.11.011","article-title":"The myostatin gene: physiology and pharmacological relevance","volume":"7","author":"Joulia-Ekaza","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mus.21244","article-title":"Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease","volume":"39","author":"Rodino-Klapac","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.phrs.2015.05.010_bib1395","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ydbio.2004.01.046","article-title":"Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis","volume":"270","author":"Amthor","year":"2004","journal-title":"Dev. Biol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5640\/insc.01011","article-title":"Formoterol may activate rat muscle regeneration during cancer cachexia","volume":"1","author":"Ametller","year":"2011","journal-title":"Insci. J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1405","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/jpet.114.217380","article-title":"Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice","volume":"351","author":"Jesinkey","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.05.010_bib1410","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/gerona\/62.8.813","article-title":"Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia","volume":"62","author":"Ryall","year":"2007","journal-title":"J. Gerontol. A: Biol. Sci. Med. Sci."},{"key":"10.1016\/j.phrs.2015.05.010_bib1415","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14712598.2014.907788","article-title":"Novel investigational biologics for the treatment of cancer cachexia","volume":"14","author":"Ma","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.phrs.2015.05.010_bib1420","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1006\/bbrc.1996.0651","article-title":"Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats","volume":"221","author":"Llovera","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2015.05.010_bib1425","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1677\/joe.1.06931","article-title":"Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats","volume":"191","author":"Granado","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1430","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivatives: emerging from the wilderness","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.phrs.2015.05.010_bib1435","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1358\/dot.2004.40.3.820083","article-title":"The promise of thalidomide: evolving indications","volume":"40","author":"Joglekar","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.phrs.2015.05.010_bib1440","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ijc.20089","article-title":"Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy","volume":"110","author":"Kedar","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2015.05.010_bib1445","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/gut.2004.053330","article-title":"Thalidomide and cancer cachexia: old problem, new hope?","volume":"54","author":"Stroud","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2015.05.010_bib1450","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jpainsymman.2011.03.007","article-title":"A Phase II dose titration study of thalidomide for cancer-associated anorexia","volume":"43","author":"Davis","year":"2012","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.phrs.2015.05.010_bib1455","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.surg.2007.09.035","article-title":"Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats","volume":"143","author":"Liu","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.phrs.2015.05.010_bib1460","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tem.2014.06.002","article-title":"TGF\u03b2 and BMP signaling in skeletal muscle: potential significance for muscle-related disease","volume":"25","author":"Sartori","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1465","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/08892220050140892","article-title":"Thalidomide for the treatment of AIDS-associated wasting","volume":"16","author":"Kaplan","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.phrs.2015.05.010_bib1470","first-page":"3349","article-title":"Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2","volume":"7","author":"Fujita","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1475","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-med-061509-131248","article-title":"Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies","volume":"62","author":"Dodson","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.phrs.2015.05.010_bib1480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13539-011-0040-8","article-title":"Breakthrough in cachexia treatment through a novel selective androgen receptor modulator","volume":"2","author":"Thum","year":"2011","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib1485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.phrs.2015.05.010_bib1490","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1495","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2474-15-291","article-title":"Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization","volume":"15","author":"Blanqu\u00e9","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.phrs.2015.05.010_bib1500","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2013.03.003","article-title":"GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy","volume":"72","author":"Cozzoli","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.05.010_bib1505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia\/cachexia","volume":"12","author":"Chasen","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.phrs.2015.05.010_bib1510","unstructured":"ClinicalTrials.gov. Open label study with OHR\/AVR118 in advanced cancer patients with anorexia\u2013cachexia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01206335."},{"key":"10.1016\/j.phrs.2015.05.010_bib1515","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/DDDT.S39771","article-title":"Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome","volume":"7","author":"Mantovani","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2015.05.010_bib1520","unstructured":"ClinicalTrials.gov. Pilot Study of APD209 in Cancer Cachexia http:\/\/clinicaltrials.gov\/show\/NCT00895726."},{"key":"10.1016\/j.phrs.2015.05.010_bib1525","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.05.010_bib1530","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2015.05.010_bib1535","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nmd.2004.10.018","article-title":"The function of myostatin and strategies of myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle","volume":"15","author":"Patel","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.phrs.2015.05.010_bib1540","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00075197-200405000-00004","article-title":"Myostatin: a therapeutic target for skeletal muscle wasting","volume":"7","author":"Roth","year":"2004","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.phrs.2015.05.010_bib1545","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2015.05.010_bib1550","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02250443."},{"key":"10.1016\/j.phrs.2015.05.010_bib1555","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01963598."},{"key":"10.1016\/j.phrs.2015.05.010_bib1560","doi-asserted-by":"crossref","first-page":"601434","DOI":"10.1155\/2011\/601434","article-title":"Cancer cachexia: mechanisms and clinical implications","volume":"2011","author":"Donohoe","year":"2011","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.phrs.2015.05.010_bib1565","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/030089161309900218","article-title":"Comparison of three different treatment modalities in the management of cancer cachexia","volume":"99","author":"Kanat","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.phrs.2015.05.010_bib1570","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jpainsymman.2003.09.007","article-title":"Systematic review of megestrol acetate in the treatment of anorexia\u2013cachexia syndrome","volume":"27","author":"Pascual L\u00f3pez","year":"2004","journal-title":"J. Pain Symptom Manage"},{"key":"10.1016\/j.phrs.2015.05.010_bib1575","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.90252.2008","article-title":"Neural control of the anorexia\u2013cachexia syndrome","volume":"295","author":"Laviano","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.05.010_bib1580","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinbiochem.2013.10.025","article-title":"Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia","volume":"47","author":"Martins","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.phrs.2015.05.010_bib1585","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(94)90229-1","article-title":"Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations","volume":"265","author":"McCarthy","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.05.010_bib1590","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00003495-200161040-00004","article-title":"Managing cancer-related anorexia\/cachexia","volume":"61","author":"Mantovani","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2015.05.010_bib1595","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clnu.2010.06.003","article-title":"Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia","volume":"29","author":"Busquets","year":"2010","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.phrs.2015.05.010_bib1600","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1096\/fj.03-1228fje","article-title":"Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass","volume":"18","author":"Jones","year":"2004","journal-title":"FASEB J."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:24:39Z","timestamp":1691727879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":160,"alternative-id":["S1043661815000948"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.05.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}